Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947260 | 1.00 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL14935796 | 1.00 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| Methane SCHEMBL4340079 | 0.98 | CYP2D6 (0.46) | CYP2D6SRCDPP4LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL8695663 | 0.98 | CYP2D6 (0.46) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL995792 | 0.83 | DPP4 (0.44) | CYP2D6SRCDPP4LMNACTSD | |
| SCHEMBL28513 | 0.83 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL29779 | 0.83 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL27675527 | 0.82 | MMP8 (0.42) | CYP2D6SLC1A2SLC1A3SLC1A1TSHR | |
| Hydrochloric Acid SCHEMBL28838130 | 0.82 | TDP1 (0.43) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL6945331 | 0.79 | KMT2A (0.56) | CYP2D6DPP4LMNAMAPK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082450-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | YAMASHITA KOKI (JP) | 2002-06-27 | — | — | US | claimed |
| EP-1046634-A1 | PROCESSES FOR PRODUCING BETA-HALOGENO-ALPHA-AMINO-CARBOXYLIC ACIDS AND PHENYLCYSTEINE DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2000-10-25 | — | — | EP | claimed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20040176301-A1 | p21 peptides | CYCLACEL LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1046634-B1 | PROCESSES FOR PRODUCING BETA-HALOGENO-ALPHA-AMINO-CARBOXYLIC ACIDS AND PHENYLCYSTEINE DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORP (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176301-A1 | p21 peptides | CDK2, CDK4, CDKN1A | CYP2D6 3617/4885SRC 1776/4885DPP4 1919/4885 |
| US-20020082450-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | BCAT1, CBS, BCAT2 | CYP2D6 524/4885SRC 1145/4885DPP4 2292/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | CYP2D6 2348/4885SRC 3133/4885DPP4 362/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | CYP2D6 2324/4885SRC 3100/4885DPP4 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.